Iha Health Services Corporation
Iha Health Services Corporation was paid $9.06M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
ANN ARBOR, MI 48103
Next to other Clinical Social Worker providers in Michigan
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,302 | $489K | |
| 2019 | 18,751 | $460K | |
| 2020 | 9,312 | $258K | |
| 2021 | 10,242 | $328K | |
| 2022 | 11,163 | $397K | |
| 2023 | 116,522 | $3.51M | |
| 2024incomplete | 123,546 | $3.61M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 43,314 | 38,902 | $2.46M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 16,401 | 15,413 | $1.31M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 10% | 12,970 | 12,964 | $936K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 9.8% | 12,949 | 12,183 | $891K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.8% | 9,964 | 9,954 | $711K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.1% | 6,025 | 6,022 | $465K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.2% | 3,233 | 3,175 | $377K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 3.6% | 12,623 | 12,464 | $327K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.2% | 9,259 | 8,967 | $287K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3.1% | 20,944 | 20,846 | $280K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.7% | 1,350 | 1,310 | $159K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 5,949 | 5,472 | $64K |
100 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 737 | $60K |
| 90480 | <1% | 1,340 | $55K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,996 | $52K |
| 99383 | <1% | 565 | $50K | |
| 87428 | <1% | 1,231 | $45K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 392 | $44K |
| 99381 | <1% | 524 | $43K | |
| 90474 | <1% | 3,733 | $43K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,037 | $41K |
| 99384 | <1% | 282 | $28K | |
| 99382 | <1% | 325 | $27K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 315 | $22K |
| 83655 | <1% | 2,120 | $21K | |
| 92551 | <1% | 3,397 | $20K | |
| 91320 | <1% | 344 | $18K | |
| 92552 | <1% | 739 | $16K | |
| 96127 | <1% | 4,214 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 374 | $14K |
| 17110 | <1% | 197 | $13K | |
| 90686 | <1% | 7,989 | $13K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 375 | $12K |
| 80061 | Lipid panel | <1% | 1,224 | $12K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 447 | $11K |
| 0154A | <1% | 263 | $10K | |
| 99188 | <1% | 1,416 | $10K | |
| 96380 | <1% | 530 | $9K | |
| 0124A | <1% | 228 | $9K | |
| 0072A | <1% | 180 | $7K | |
| 0071A | <1% | 149 | $6K | |
| 90677 | <1% | 3,265 | $6K | |
| 0081A | <1% | 136 | $5K | |
| 0173A | <1% | 116 | $5K | |
| 90651 | <1% | 3,209 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 784 | $4K |
| 81003 | <1% | 2,301 | $4K | |
| 85018 | <1% | 2,099 | $4K | |
| 90656 | <1% | 1,854 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 37 | $4K |
| 0082A | <1% | 89 | $3K | |
| 99177 | <1% | 935 | $3K | |
| 90620 | <1% | 136 | $3K | |
| 0174A | <1% | 54 | $2K | |
| 81025 | <1% | 313 | $2K | |
| 99051 | <1% | 704 | $2K | |
| 69210 | <1% | 60 | $2K | |
| 90473 | <1% | 554 | $2K | |
| 90715 | <1% | 1,598 | $2K | |
| 17250 | <1% | 28 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 178 | $1K |
| 96381 | <1% | 63 | $1K | |
| 90734 | <1% | 564 | $855.72 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 122 | $846.33 |
| 99462 | <1% | 31 | $737.87 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 12 | $722.64 |
| 81002 | <1% | 235 | $615.91 | |
| 0074A | <1% | 13 | $501.05 | |
| 90619 | <1% | 1,760 | $488.22 | |
| G9001 | Coordinated care fee, initial rate | <1% | 348 | $487.24 |
| 0054A | <1% | 12 | $467.28 | |
| 96161 | <1% | 143 | $217.14 | |
| 94664 | <1% | 18 | $187.32 | |
| 98966 | <1% | 3,573 | $136.33 | |
| 99000 | <1% | 44 | $134.00 | |
| 90716 | <1% | 4,554 | $92.51 | |
| 90707 | <1% | 4,543 | $77.15 | |
| 91319 | <1% | 307 | $39.98 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26 | $25.49 |
| 98967 | <1% | 1,314 | $24.88 | |
| 36416 | <1% | 30 | $15.36 | |
| G9007 | Coordinated care fee, scheduled team conference | <1% | 268 | $0.50 |
| 98968 | <1% | 307 | $0.36 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 591 | $0.16 |
| 3008F | 0% | 36,110 | $0.00 | |
| 3048F | 0% | 449 | $0.00 | |
| 90697 | 0% | 5,098 | $0.00 | |
| 90698 | 0% | 3,411 | $0.00 | |
| 90744 | 0% | 1,134 | $0.00 | |
| 90680 | 0% | 6,296 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 27 | $0.00 |
| 90696 | 0% | 1,864 | $0.00 | |
| 90381 | 0% | 219 | $0.00 | |
| 3074F | 0% | 711 | $0.00 | |
| 91318 | 0% | 395 | $0.00 | |
| 91315 | 0% | 186 | $0.00 | |
| 91317 | 0% | 148 | $0.00 | |
| 0240U | 0% | 222 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 17 | $0.00 |
| G9008 | Coordinated care fee, physician coordinated care oversight services | 0% | 37 | $0.00 |
| 91307 | 0% | 64 | $0.00 | |
| 90670 | 0% | 5,126 | $0.00 | |
| 90633 | 0% | 4,962 | $0.00 | |
| 90461 | 0% | 5,234 | $0.00 | |
| 99173 | 0% | 1,917 | $0.00 | |
| 91312 | 0% | 170 | $0.00 | |
| 3078F | 0% | 681 | $0.00 | |
| 90700 | 0% | 223 | $0.00 | |
| 90685 | 0% | 723 | $0.00 | |
| 90380 | 0% | 251 | $0.00 | |
| 91308 | 0% | 179 | $0.00 | |
| 90713 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.